Kelun-Biotech (SKB BIO-B) Secures HKEX Nod for Full H-Share Circulation, Converting 8.21 Million Shares

Bulletin Express

Apr 08

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (SKB BIO-B) has received Hong Kong Stock Exchange approval to convert and list 8.21 million domestic and unlisted foreign shares as H shares under its Full Circulation programme, the company disclosed on 8 April 2026.

The newly converted shares represent 3.52% of Kelun-Biotech’s total share capital. Upon completion, the proportion of H shares in issue will rise from 69.80% to 73.32%, while domestic shares will fall from 28.21% to 26.68%. All unlisted foreign shares (previously 1.99% of capital) will be eliminated.

Kelun-Biotech will now proceed with the remaining conversion and trading formalities and will update the market on further progress. Shareholders and potential investors are advised to exercise caution when dealing in the company’s securities.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1161871922"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1161871922\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1161871922?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-08 21:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1161871922","market":"hk","top_or_hot":-1,"title":"Kelun-Biotech (SKB BIO-B) Secures HKEX Nod for Full H-Share Circulation, Converting 8.21 Million Shares","media":"Bulletin Express","content":"<p>Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (SKB BIO-B) has received Hong Kong Stock Exchange approval to convert and list 8.21 million domestic and unlisted foreign shares as H shares under its Full Circulation programme, the company disclosed on 8 April 2026.</p>\n<p>The newly converted shares represent 3.52% of Kelun-Biotech’s total share capital. Upon completion, the proportion of H shares in issue will rise from 69.80% to 73.32%, while domestic shares will fall from 28.21% to 26.68%. All unlisted foreign shares (previously 1.99% of capital) will be eliminated.</p>\n<p>Kelun-Biotech will now proceed with the remaining conversion and trading formalities and will update the market on further progress. Shareholders and potential investors are advised to exercise caution when dealing in the company’s securities.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kelun-Biotech (SKB BIO-B) Secures HKEX Nod for Full H-Share Circulation, Converting 8.21 Million Shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKelun-Biotech (SKB BIO-B) Secures HKEX Nod for Full H-Share Circulation, Converting 8.21 Million Shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-04-08 21:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (SKB BIO-B) has received Hong Kong Stock Exchange approval to convert and list 8.21 million domestic and unlisted foreign shares as H shares under its Full Circulation programme, the company disclosed on 8 April 2026.</p>\n<p>The newly converted shares represent 3.52% of Kelun-Biotech’s total share capital. Upon completion, the proportion of H shares in issue will rise from 69.80% to 73.32%, while domestic shares will fall from 28.21% to 26.68%. All unlisted foreign shares (previously 1.99% of capital) will be eliminated.</p>\n<p>Kelun-Biotech will now proceed with the remaining conversion and trading formalities and will update the market on further progress. Shareholders and potential investors are advised to exercise caution when dealing in the company’s securities.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06990","symbol_name":"科伦博泰生物","start_time":0,"source_url":"","article_id":"1161871922","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1161871922","pubTimestamp":1775654495,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (SKB BIO-B) has received Hong Kong Stock Exchange approval to convert and list 8.21 million domestic and unlisted foreign shares as H shares under...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06990":"科伦博泰生物"},"translate_title":"科伦生物（SKB BIO-B）获得港交所批准H股全流通，转换821万股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06990":1},"content_text":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (SKB BIO-B) has received Hong Kong Stock Exchange approval to convert and list 8.21 million domestic and unlisted foreign shares as H shares under its Full Circulation programme, the company disclosed on 8 April 2026.\nThe newly converted shares represent 3.52% of Kelun-Biotech’s total share capital. Upon completion, the proportion of H shares in issue will rise from 69.80% to 73.32%, while domestic shares will fall from 28.21% to 26.68%. All unlisted foreign shares (previously 1.99% of capital) will be eliminated.\nKelun-Biotech will now proceed with the remaining conversion and trading formalities and will update the market on further progress. Shareholders and potential investors are advised to exercise caution when dealing in the company’s securities.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}